** Shares of Abbott India Ltd ABOT.NS climb 4.4% to 29,030 rupees
** JP Morgan ("overweight") lifts PT on stock to 34,000 rupees from 31,500 rupees, a Street-high, as per data compiled by LSEG
** Drugmaker's Q3 consol net profit jumped 16% Y/Y on Wednesday, stock jumped ~4%
** ABOT benefitted from its unique strategy of tailoring product launches to fit local markets, says JPM
** Adds, strong demand for Rybelsus, oral version of Novo Nordisk's NOVOb.CO weight-loss drug, boosted sales
** Avg rating of four analysts on ABOT at "strong buy"; median PT is 31,850 rupees - LSEG data
** Stock gained ~30% in 2024
(Reporting by Nandan Mandayam in Bengaluru)
((Nandan.Mandayam@thomsonreuters.com; Mobile: +91 9591011727;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。